Mylan launches block deal to sell minority stake in Biocon for up to $363 million
Viatris subsidiary Mylan has initiated a block deal to sell its minority stake in Biocon worth approximately $363 million. The transaction involves the offloading of 92 million equity shares as part of a strategic financial exit.
Viatris subsidiary Mylan has launched a block deal to divest its minority stake in Biocon, seeking to raise up to $363 million through the sale of 92 million equity shares. This move follows a period of consolidation after Biocon Biologics acquired the global biosimilars business of Viatris in 2022.
The sale price is expected to be finalized through the block deal mechanism, which typically involves large-scale trades between institutional investors. Market data indicates that this divestment represents a significant portion of Mylan's remaining equity holding in the Indian biopharmaceutical company.
The exit marks a transition in the partnership between the two entities, shifting away from a joint ownership structure toward an independent operational model for their biosimilar assets. Financial analysts view this as a capital reallocation strategy by Viatris to streamline its global portfolio. Source: Market Reports.
